0001174947-21-000705.txt : 20210728 0001174947-21-000705.hdr.sgml : 20210728 20210728162756 ACCESSION NUMBER: 0001174947-21-000705 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20210728 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20210728 DATE AS OF CHANGE: 20210728 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CONMED Corp CENTRAL INDEX KEY: 0000816956 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] IRS NUMBER: 160977505 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39218 FILM NUMBER: 211122859 BUSINESS ADDRESS: STREET 1: 11311 CONCEPT BOULEVARD CITY: LARGO STATE: FL ZIP: 33773 BUSINESS PHONE: 727-214-2974 MAIL ADDRESS: STREET 1: 11311 CONCEPT BOULEVARD CITY: LARGO STATE: FL ZIP: 33773 FORMER COMPANY: FORMER CONFORMED NAME: CONMED CORP DATE OF NAME CHANGE: 19920703 8-K 1 form8k-26491_cnmd.htm 8-K
0000816956 false 0000816956 2021-07-28 2021-07-28 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

 

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

PURSUANT TO SECTION 13 OR 15 (d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

 

Date of Report (Date of earliest event reported): July 28, 2021

 

 

CONMED CORPORATION

(Exact name of registrant as specified in its charter)

 

Delaware 001-39218 16-0977505
(State or other jurisdiction of (Commission File Number) (I.R.S. Employer
incorporation or organization)   Identification No.)

 

 

11311 Concept Blvd

Largo, Florida 33773

(Address of principal executive offices, including zip code)

 

(727) 392-6464

(Registrant's telephone number, including area code)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions (See General Instruction A.2 below):

 

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Rule 12(b) of the Act

 

Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock, $0.01 par value CNMD NYSE

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

Item 2.02 Results of Operations and Financial Condition.

 

On July 28, 2021, CONMED Corporation issued a press release announcing financial results for the second quarter ended June 30, 2021. A copy of this press release is attached hereto as Exhibit 99.1.

 

The information in this Current Report on Form 8-K that is furnished under “Item 2.02. Results of Operations and Financial Condition” and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Act of 1934, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by specific reference in such filing.

 

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

 

The following exhibits are included herewith:

 

 

  Exhibit No. Description of Exhibit
     
  99.1 Press Release dated July 28, 2021, issued by CONMED Corporation.
     
  104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 

 

 

 

 

 

 

Signature

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

Date:     July 28, 2021 CONMED CORPORATION
               (Registrant)
     
     
       By: /s/  Todd W. Garner
  Name: Todd W. Garner
    Title: Executive Vice President-
      Chief Financial Officer

 

 

 

 

 EX-99.1 2 ex99-1.htm EX-99.1

 

 

NEWS RELEASE
   
  CONTACT:
  CONMED Corporation
  Todd W. Garner
  Chief Financial Officer
  727-214-2975
  ToddGarner@conmed.com

 

 

CONMED Corporation Announces Second Quarter Financial Results

 

Largo, Florida, July 28, 2021 – CONMED Corporation (NYSE: CNMD) today announced financial results for the second quarter ended June 30, 2021.

 

Second Quarter 2021 Highlights

 

·Sales of $255.2 million increased 61.7% year over year as reported and 58.2% in constant currency.
·Domestic revenue increased 64.2% year over year.
·International revenue increased 58.6% year over year as reported and 50.7% in constant currency.
·Diluted net earnings per share (GAAP) were $0.41, compared to a diluted net loss per share of $0.96 during the second quarter of 2020.
·Adjusted diluted net earnings per share(1) were $0.71, compared to an adjusted diluted net loss per share of $0.07 during the second quarter of 2020.

 

“Our solid second quarter results, driven by the strong commitment and exceptional performance of our global team, have positioned us well as we continue to navigate the COVID-19 environment and its impacts on our business,” commented Curt R. Hartman, CONMED’s Chair of the Board, President, and Chief Executive Officer. “Our focus remains on new product innovation and strategically investing in our commercial and operations teams to better serve our global customers and drive shareholder value.”

 

2021 Outlook

 

Based on its first six-month results, the Company is increasing its guidance for the full year 2021 and now expects revenue between $1.015 billion and $1.035 billion, compared to its prior guidance of between $1.0 billion and $1.03 billion. Based on recent exchange rates, the Company continues to expect the positive impact to 2021 sales from foreign exchange in the range of 50 to 100 basis points.

 

The Company now expects full-year 2021 adjusted diluted net earnings per share in the range of $3.15 to $3.25, compared to its prior range of $3.05 to $3.20.

 

Supplemental Financial Disclosures

 

(1) A reconciliation of reported diluted net earnings (loss) per share to adjusted diluted net earnings (loss) per share, a non-GAAP financial measure, appears below.

 

 

 

 

Conference Call

 

The Company’s management will host a conference call today at 4:30 p.m. ET to discuss its second quarter 2021 results.

 

To participate in the conference call, dial 1-844-889-7792 (domestic) or +1-661-378-9936 (international) and refer to the passcode 7138188.

 

This conference call will also be webcast and can be accessed from the “Investors” section of CONMED's website at www.conmed.com. The webcast replay of the call will be available at the same site approximately one hour after the end of the call.

 

A recording of the call will also be available from 7:30 p.m. ET on Wednesday, July 28, 2021, until 7:30 p.m. ET on Wednesday, August 4, 2021. To hear this recording, dial 1-855-859-2056 (domestic) or +1-404-537-3406 (international) and enter the passcode 7138188.

 

 

 

 

 

Consolidated Condensed Statements of Income (Loss)

(in thousands, except per share amounts, unaudited)

 

   Three Months Ended  Six Months Ended
   June 30,  June 30,
   2021  2020  2021  2020
             
Net sales  $255,161   $157,785   $487,837   $371,796 
Cost of sales   113,737    85,856    217,964    180,707 
Gross profit   141,424    71,929    269,873    191,089 
% of sales   55.4%    45.6%    55.3%    51.4% 
Selling & administrative expense   104,399    84,475    202,739    180,343 
Research & development expense   11,318    8,700    21,344    18,820 
Income (loss) from operations   25,707    (21,246)   45,790    (8,074)
% of sales   10.1%    -13.5%    9.4%    -2.2% 
Interest expense   9,420    11,401    19,772    20,993 
Other expense   —    89    —    178 
Income (loss) before income taxes   16,287    (32,736)   26,018    (29,245)
Provision (benefit) for income taxes   2,997    (5,336)   2,868    (7,772)
Net income (loss)  $13,290   $(27,400)  $23,150   $(21,473)
                     
Basic EPS  $0.46   $(0.96)  $0.80   $(0.75)
Diluted EPS   0.41    (0.96)   0.72    (0.75)
                     
Basic shares   29,125    28,542    29,052    28,506 
Diluted shares   32,464    28,542    31,964    28,506 

 

 

 

 

Sales Summary

(in millions, unaudited)

 

   Three Months Ended June 30,
         % Change
                  Domestic  International
   2021  2020  As
Reported		  Impact
of
Foreign
Currency		  Constant
Currency		  As
Reported		  As
Reported		  Impact of
Foreign
Currency		  Constant
Currency
Orthopedic Surgery  $107.9   $60.5    78.4%    -5.5%    72.9%    90.7%    71.7%    -8.6%    63.1% 
General Surgery   147.3    97.3    51.4%    -2.3%    49.1%    55.7%    42.2%    -7.0%    35.2% 
   $255.2   $157.8    61.7%    -3.5%    58.2%    64.2%    58.6%    -7.9%    50.7% 
                                              
Single-use Products  $208.9   $128.5    62.6%    -3.6%    59.0%    55.8%    72.7%    -8.8%    63.9% 
Capital Products   46.3    29.3    58.0%    -3.4%    54.6%    126.6%    19.9%    -5.4%    14.5% 
   $255.2   $157.8    61.7%    -3.5%    58.2%    64.2%    58.6%    -7.9%    50.7% 
                                              
Domestic  $143.6   $87.4    64.2%    0.0%    64.2%                     
International   111.6    70.4    58.6%    -7.9%    50.7%                     
   $255.2   $157.8    61.7%    -3.5%    58.2%                     
                                              

 

   Six Months Ended June 30,
         % Change
                  Domestic  International
   2021  2020  As
Reported		  Impact
of
Foreign
Currency		  Constant
Currency		  As
Reported		  As
Reported		  Impact of
Foreign
Currency		  Constant
Currency
Orthopedic Surgery  $215.0   $159.8    34.6%    -3.3%    31.3%    33.3%    35.3%    -5.1%    30.2% 
General Surgery   272.8    212.0    28.7%    -1.7%    27.0%    28.3%    29.6%    -5.5%    24.1% 
   $487.8   $371.8    31.2%    -2.3%    28.9%    29.7%    33.1%    -5.3%    27.8% 
                                              
Single-use Products  $396.3   $306.2    29.4%    -2.2%    27.2%    26.3%    33.7%    -5.4%    28.3% 
Capital Products   91.5    65.6    39.6%    -2.8%    36.8%    51.1%    31.0%    -4.9%    26.1% 
   $487.8   $371.8    31.2%    -2.3%    28.9%    29.7%    33.1%    -5.3%    27.8% 
                                              
Domestic  $267.5   $206.3    29.7%    0.0%    29.7%                     
International   220.3    165.5    33.1%    -5.3%    27.8%                     
   $487.8   $371.8    31.2%    -2.3%    28.9%                     

 

 

 

Reconciliation of Reported Net Income (Loss) to Adjusted Net Income (Loss)

(in thousands, except per share amounts, unaudited)

   Three Months Ended June 30, 2021
   Gross Profit  Selling &
Administrative
Expense		  Operating
Income		  Interest
Expense		  Tax
Expense		  Effective
Tax Rate		  Net Income  Diluted EPS
As reported  $141,424   $104,399   $25,707   $9,420   $2,997    18.4%   $13,290   $0.41 
% of sales   55.4%    40.9%    10.1%                          
   $141,424   $104,399   $25,707   $9,420   $2,997        $13,290      
Adjusted gross profit %   55.4%                                    
Amortization(6)  $1,500    (6,689)   8,189    (3,586)   2,886         8,889      
Adjusted net income       $97,710   $33,896   $5,834   $5,883    21.0%   $22,179   $0.71 
% of sales        38.3%    13.3%                          
                                         
Diluted shares outstanding                                      30,482 
Additional potential dilutive shares from in-the-money convertible notes(7)         1,982 
Diluted shares, as reported                                      32,464 
Convertible note hedges(8)                                      (1,362)
Diluted shares, as adjusted                                      31,102 
                                         

 

   Three Months Ended June 30, 2020
   Gross Profit  Selling &
Administrative
Expense		  Operating
Income (Loss)		  Interest
Expense		  Tax
Expense/
(Benefit)		  Effective
Tax Rate		  Net Income
(Loss)		  Diluted EPS
As reported  $71,929   $84,475   $(21,246)  $11,401   $(5,336)   16.3%   $(27,400)  $(0.96)
% of sales   45.6%    53.5%    -13.5%                          
Plant utilization costs (1)   6,586    —    6,586    —    739         5,847      
Product rationalization costs (2)   2,169    (2,095)   4,264    —    460         3,804      
Restructuring and related costs (3)   1,087    (2,124)   3,211    —    346         2,865      
Manufacturing consolidation costs (4)   1,602    —    1,602    —    144         1,458      
Acquisition and integration costs (5)   652    (439)   1,091    —    119         972      
   $84,025   $79,817   $(4,492)  $11,401   $(3,528)       $(12,454)     
Adjusted gross profit %   53.3%                                    
Amortization(6)  $1,500    (6,955)   8,455    (3,413)   1,280         10,588      
Adjusted net income (loss)       $72,862   $3,963   $7,988   $(2,248)   54.6%   $(1,866)  $(0.07)
% of sales        46.2%    2.5%                          

 

 

 

(1) In 2020, the Company incurred a charge related to plant underutilization due to abnormally low production as a result of decreased sales caused by the COVID-19 pandemic.

(2) In 2020, the Company performed an analysis of product lines and determined certain catalog numbers, principally related to capital equipment, would be discontinued and consolidated into existing product offerings resulting in a charge to cost of sales.  The Company also wrote-off related field inventory used for customer demonstration and evaluation of the discontinued products to selling and administrative expense.

(3) In 2020, the Company incurred restructuring costs related to a voluntary separation arrangement with employees as a result of the COVID-19 pandemic and restructuring of our sales force.

(4) In 2020, the Company incurred costs related to the consolidation of certain manufacturing operations.  These costs related to winding down operations at certain locations and moving production lines to other facilities.

(5) In 2020, the Company incurred inventory adjustments associated with a prior acquisition and severance and integration costs mainly related to the Buffalo Filter, LLC acquisition.

(6) Includes amortization of intangible assets, deferred financing fees and debt discount.

(7) In 2021, the Company's average share price exceeded the conversion price of our 2.625% convertible notes due in 2024 (the "Notes") resulting in additional potential diluted shares.

(8) Non-GAAP adjusted dilutive weighted average shares outstanding exclude dilution that is expected to be offset by the Company's convertible note hedge transactions.    

 

 

 

 

Reconciliation of Reported Net Income (Loss) to Adjusted Net Income

(in thousands, except per share amounts, unaudited)

   Six Months Ended June 30, 2021
   Gross Profit  Selling &
Administrative
Expense		  Operating
Income		  Interest
Expense		  Tax
Expense		  Effective
Tax Rate		  Net Income  Diluted EPS
As reported  $269,873   $202,739   $45,790   $19,772   $2,868    11.0%   $23,150   $0.72 
% of sales   55.3%    41.6%    9.4%                          
Restructuring and related costs (1)   —    (414)   414    —    109         305      
   $269,873   $202,325   $46,204   $19,772   $2,977        $23,455      
Adjusted gross profit %   55.3%                                    
Amortization(6)  $3,000    (13,527)   16,527    (7,147)   5,855         17,819      
Adjusted net income       $188,798   $62,731   $12,625   $8,832    17.6%   $41,274   $1.34 
% of sales        38.7%    12.9%                          
                                         
Diluted shares outstanding                                      30,352 
Additional potential dilutive shares from in-the-money convertible notes(7)     1,612 
Diluted shares, as reported                                      31,964 
Convertible note hedges(8)                                      (1,201)
Diluted shares, as adjusted                                      30,763 

 

   Six Months Ended June 30, 2020
   Gross Profit  Selling &
Administrative
Expense		  Operating
Income (Loss)		  Interest
Expense		  Tax
Expense/
(Benefit)		  Effective
Tax Rate		  Net Income
(Loss)		  Diluted EPS
As reported  $191,089   $180,343   $(8,074)  $20,993   $(7,772)   26.6%   $(21,473)  $(0.75)
% of sales   51.4%    48.5%    -2.2%                          
Plant utilization costs (2)   6,586    —    6,586    —    739         5,847      
Product rationalization costs (3)   2,169    (2,095)   4,264    —    460         3,804      
Restructuring and related costs (1)   1,087    (2,124)   3,211    —    346         2,865      
Manufacturing consolidation costs (4)   3,387    —    3,387    —    837         2,550      
Acquisition and integration costs (5)   1,457    (1,192)   2,649    —    722         1,927      
   $205,775   $174,932   $12,023   $20,993   $(4,668)       $(4,480)     
Adjusted gross profit %   55.3%                                    
Amortization(6)  $3,000    (13,954)   16,954    (6,497)   5,775         17,676      
Adjusted net income       $160,978   $28,977   $14,496   $1,107    7.7%   $13,196   $0.46 
% of sales        43.3%    7.8%                          

 

 

 

(1) In 2021, the Company incurred restructuring costs related to restructuring of our sales force. In 2020, the Company incurred restructuring costs related to a voluntary separation arrangement with employees as a result of the COVID-19 pandemic and restructuring of our sales force.

(2) In 2020, the Company incurred a charge related to plant underutilization due to abnormally low production as a result of decreased sales caused by the COVID-19 pandemic.

(3) In 2020, the Company performed an analysis of product lines and determined certain catalog numbers, principally related to capital equipment, would be discontinued and consolidated into existing product offerings resulting in a charge to cost of sales.  The Company also wrote-off related field inventory used for customer demonstration and evaluation of the discontinued products to selling and administrative expense.

(4) In 2020, the Company incurred costs related to the consolidation of certain manufacturing operations.  These costs related to winding down operations at certain locations and moving production lines to other facilities.

(5) In 2020, the Company incurred inventory adjustments associated with a prior acquisition and severance and integration costs mainly related to the Buffalo Filter, LLC acquisition.

(6) Includes amortization of intangible assets, deferred financing fees and debt discount.

(7) In 2021, the Company's average share price exceeded the conversion price of our 2.625% convertible notes due in 2024 (the "Notes") resulting in additional potential diluted shares.

(8) Non-GAAP adjusted dilutive weighted average shares outstanding exclude dilution that is expected to be offset by the Company's convertible note hedge transactions.       

 

 

 

Reconciliation of Reported Net Income (Loss) to EBITDA & Adjusted EBITDA

(in thousands, unaudited)

   Three Months Ended  Six Months Ended
   June 30,  June 30,
   2021  2020  2021  2020
             
Net income (loss)  $13,290   $(27,400)  $23,150   $(21,473)
Provision (benefit) for income taxes   2,997    (5,336)   2,868    (7,772)
Interest expense   9,420    11,401    19,772    20,993 
Depreciation   3,984    4,588    8,741    9,234 
Amortization   13,797    13,616    27,316    27,392 
EBITDA  $43,488   $(3,131)  $81,847   $28,374 
                     
Stock based compensation   4,290    3,555    7,676    6,587 
Plant underutilization costs   —    6,586    —    6,586 
Product rationalization costs   —    4,264    —    4,264 
Restructuring and related costs   —    3,211    414    3,211 
Manufacturing consolidation costs   —    1,602    —    3,387 
Acquisition and integration costs   —    1,091    —    2,649 
Adjusted EBITDA  $47,778   $17,178   $89,937   $55,058 
                     
                     
EBITDA Margin                    
  EBITDA   17.0%    -2.0%    16.8%    7.6% 
  Adjusted EBITDA   18.7%    10.9%    18.4%    14.8% 

 

 

 

 

 

About CONMED Corporation

 

CONMED is a medical technology company that provides surgical devices and equipment for minimally invasive procedures. The Company’s products are used by surgeons and physicians in a variety of specialties, including orthopedics, general surgery, gynecology, neurosurgery, thoracic surgery, and gastroenterology. For more information, visit www.conmed.com.

 

 

Forward-Looking Statements

 

This press release and today’s conference call may contain forward-looking statements based on certain assumptions and contingencies that involve risks and uncertainties, which could cause actual results, performance, or trends to differ materially from those expressed in the forward-looking statements herein or in previous disclosures. For example, in addition to general industry and economic conditions, factors that could cause actual results to differ materially from those in the forward-looking statements may include, but are not limited to, the risks posed to the Company’s business, financial condition, and results of operations by the COVID-19 global pandemic and the various government responses to the pandemic, including deferral of surgeries, reductions in hospital and ambulatory surgery center operating volumes, disruption to potential supply chain reliability, as well as the risk factors discussed in the Company's Annual Report on Form 10-K for the full year ended December 31, 2020 and listed under the heading Forward-Looking Statements in the Company’s most recently filed Form 10-Q. Any and all forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and relate to the Company’s performance on a going-forward basis. The Company believes that all forward-looking statements made by it have a reasonable basis, but there can be no assurance that management’s expectations, beliefs or projections as expressed in the forward-looking statements will actually occur or prove to be correct.

 

 

Supplemental Information - Reconciliation of GAAP to Non-GAAP Financial Measures

 

The Company supplements the reporting of its financial information determined under accounting principles generally accepted in the United States (GAAP) with certain non-GAAP financial measures, including percentage sales growth in constant currency; adjusted gross profit; cost of sales excluding specified items; adjusted selling and administrative expenses; adjusted operating income (loss); adjusted interest expense; adjusted income tax expense (benefit); adjusted effective income tax rate; adjusted net income (loss), adjusted diluted shares and adjusted diluted net earnings (loss) per share (EPS). The Company believes that these non-GAAP measures provide meaningful information to assist investors and shareholders in understanding its financial results and assessing its prospects for future performance. Management believes percentage sales growth in constant currency and the other adjusted measures described above are important indicators of its operations because they exclude items that may not be indicative of, or are unrelated to, its core operating results and provide a baseline for analyzing trends in the Company’s underlying business. Further, the presentation of EBITDA is a non-GAAP measurement that management considers useful for measuring aspects of the Company’s cash flow. Management uses these non-GAAP financial measures for reviewing the operating results and analyzing potential future business trends in connection with its budget process and bases certain management incentive compensation on these non-GAAP financial measures.

 

Net sales on a constant currency basis is a non-GAAP measure. The Company analyzes net sales on a constant currency basis to better measure the comparability of results between periods. To measure percentage sales growth in constant currency, the Company removes the impact of changes in foreign currency exchange rates that affect the comparability and trend of net sales. To measure earnings performance on a consistent and comparable basis, the Company excludes certain items that affect the comparability of operating results and the trend of earnings. These adjustments are irregular in timing, may not be indicative of past and future performance and are therefore excluded to allow investors to better understand underlying operating trends.

 

 

 

Because non-GAAP financial measures are not standardized, it may not be possible to compare these financial measures with other companies' non-GAAP financial measures having the same or similar names. These adjusted financial measures should not be considered in isolation or as a substitute for reported sales growth, gross profit, cost of sales, selling and administrative expenses, operating income (loss), interest expense, income tax expense (benefit), effective income tax rate, net income (loss), diluted shares and diluted net earnings (loss) per share, the most directly comparable GAAP financial measures. These non-GAAP financial measures are an additional way of viewing aspects of the Company’s operations that, when viewed with GAAP results and the reconciliations to corresponding GAAP financial measures above, provide a more complete understanding of the business. The Company strongly encourages investors and shareholders to review its financial statements and publicly filed reports in their entirety and not to rely on any single financial measure.

 

 

 

 

 GRAPHIC 3 image_001.jpg GRAPHIC begin 644 image_001.jpg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
    >)D\(^"]1U@D> M=''LMU/\4K<)]>3D^P-=)7S?^T3XJ^V:U9>&;>3,5DOVBY /65A\H/T4Y_X' M0!XE)(\LC22,7=R69F.22>I--HHH *O:+J#:3KNGZDF=UIHJC_;6E?]!.S_ ._Z_P"-']M:5_T$[/\ [_K_ (T 7J*H_P!M:5_T$[/_ M +_K_C1_;6E?]!.S_P"_Z_XT 7J*H_VUI7_03L_^_P"O^-']M:5_T$[/_O\ MK_C0!>HJC_;6E?\ 03L_^_Z_XU/;WEK>!C;7,,^W[WE2!L?7% $]%%4IM8TR MWE:*;4;2.1>&1YU4CZ@F@"[16?\ V]H__06L?_ A/\:/[>T?_H+6/_@0G^- M&A16?_;VC_\ 06L?_ A/\:/[>T?_ *"UC_X$)_C0!H451&M:4<8U.S.?2=?\ M:FCOK28@174#_P"[(#0!8HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** .!^-7_)(M=^D'_H^.OCZOL'XU?\DBUWZ0?^CXZ^/J "BBB@ HHHH **** M "BBB@ HHHH ***]E^&_P-O-<\G5?$ZRV>FG#1VGW9IQ[_W%_4^W!H X/P7X M UWQS?>3IEOMMD;$UY+D11?CW/L.?PYKZB\"_#/0O EL&M(_M.I,N);Z91O/ MJ%'\"^P_$FNJT[3K+2;"*QT^UBMK6%=L<42[545:H ***@O;VVTZRFO+R=(+ M:!#)+*YP%4=2: (-8UBPT#2;C4]3N%M[2W7<[M^@ [D] .YKY'^)'Q)U#Q[J MO\=OI$#'[-:9_P#'W]6/Z=!W)F^*/Q)NO'>L&*!GAT6V8_9H#QO/3S'']X]A MV''J3P% !1110 4444 %%%% !1110 4444 %%%% !1110!I>'O\ D9=*_P"O MR'_T,5]VU\)>'O\ D9=*_P"OR'_T,5]VT %%%% !1110 4444 4M6U6ST/2; MK5+^416MK&9)'/H.P]2>@']>I_M!>.#=W\7A*QE_F,\W\&_AM_PF.L'5-3A)T2R<;E/2XDZA M/H."WX#OQ]6JJHH55"J!@ # H 6BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** .%O/AKI__ L;3/&.F[+6YADZHHH **** "BBB@ HJM?ZA9Z58RWM_=I+ M#P>AABY5M0F3YV_W$/W1[GGV% 'M?B3QCH'A*V\[6M2AMBPRD6=TC_[J#D_7 MI7BGB?\ :-NYB\'AG2TMTZ"ZO?F<^X0' _$GZ5X?>7MUJ%W)=7MS+<7$AR\L MSEF8^Y/-04 ;NN^,O$?B5V;6-9N[I3SY3/MC'T084?E6%110 4444 %%%% ! M1110!MZ'XP\1>&G#:/K%W:*#GRUDS&?JARI_$5ZSX8_:-O8"D'B;3$N8^AN; M/Y)![E#\I/T*UX710!]P>&O&GA_Q?;F71=2BN&49>$_+*GU0\CZ]/>M^O@:U MN[FQNH[JTN);>XC.Y)8G*LI]01R*]N\"?M W5JT5AXO0W,'"B_A3]XG^^HX8 M>XY]C0!]%T55T[4K+5["*^TZZBNK64;DEB;4W_ * :^%* /?/@U\7/*^S^%O$=Q^[X MCL;R0_=](W/IZ'\/2OH.O@"OH?X-?%S[4(/"_B.X_?C$=E>2'_6>D;G^]Z'O MTZXR >\4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7Q)\0?^2C> M)/\ L)W'_HPU]MU\2?$'_DHWB3_L)W'_ *,- '-T444 ?>NF?\@JS_ZX)_Z" M*M55TS_D%6?_ %P3_P!!%6J "BBB@ KYW_:5U+?J6@Z4K?ZJ&2Y<>NXA5_\ M0&_.OHBOD;XY:G_:/Q3U! V4LXXK93]%#'_QYFH \YHHHH **** .V^%/BK_ M (1/Q]8W4LFRSN3]ENLG@(Y'S'Z-M;Z U]DU\ 5]C?"7Q5_PE?@"QGEDW7MH M/LESD\ED PQ^J[3]2: .YHHHH **** "BBB@ HHHH **** "BBB@ HHHH HZ MSJMMH>BWNJWC;;>TA:9_4@#.![GH/K7PYK.JW.N:U>ZI>-NN+N9IG] 2@ HHHH M **** "BBB@ HHHH **** "OH7]F?_CS\2?]=+?^4E?/5?0O[,__ !Y^)/\ MKI;_ ,I* />J^-/BU_R53Q!_U\#_ - 6OLNOC3XM?\E4\0?]? _] 6@#BZ** M* "BBB@ HHHH L6]_>6AS;7<\/\ USD*_P JW++X@>,-/(^S>)=54#HKW3NO M_?+$BN;HH ].TSX]>.; @7%U::@H[7-L!Q]4VFN\T3]I*PE98]W[&:TD M$@^NUL$#\37SK10!]N>'?'GACQ4%&D:Q;S3$?\>['9+_ -\-@_B.*Z.O@%69 M'#(Q5E.00<$&O2O"'QN\4^&BD%[-_:]@.#%=,?,4?[,G7\\B@#ZTHKD?!GQ( M\.^-X0--NO+O57,EE/A95]2!T8>XS[XKKJ "BBB@ HHHH **** "BBB@#@?C M5_R2+7?I!_Z/CKX^K[!^-7_)(M=^D'_H^.OCZ@ HHHH **** "BBB@ HHHH M*M:=IUYJU_#8:?;27-U,VV.*-$]7\8ZPFFZ1;F20\R2-PD2_WG/8 M?J>V:^L? 'PWTCP%I^VV47&HR+BXO77YG_V5_NK[?GF@#E?AI\%;+PR(=6U] M8KW5QAHXOO16Q]O[S#UZ#MZUZY110 4444 %?,?QO^)1U[47\,Z3/_Q*[1\7 M,B'BXE!Z>ZJ?S//85Z;\:O'I\)>&1IUA+MU;4E*1LIYABZ,_L>P]R3VKY/H M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#2\/?\C+I7_7Y#_P"A MBONVOA+P]_R,NE?]?D/_ *&*^[: "BBB@ HHHH *P_&'B.#PEX4U#6I@&^SQ M$QH3]^0\(OXDC\,UN5\[_M&^*#-?Z?X8@D^2!?M=R >KG(0'Z#AV MFD:='Y=M;($7U8]V/N3DGZUI444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 5S?C+QMH_@?2#?:I-F1LB"V0_O)F] /3U M/0?E4'CWQYIO@/0S>W9$MW+E;6U#8:9OZ*.Y_J0*^0O$GB75/%>M3:KJUP9K MB3@ <+&O95'8#_/- &KXX^(6M^.]0\[4)?*LT;,%E&Q\N,>O^TW^T?T'%@'N>*]^\%_L]V5JL=YXLN/MYH \#TC0=6U^Z^S:3IUS>S=UAC+;?J9\Z4?@OR_P#CU?2NGZ;8Z39I9Z=9P6ELGW8H(PBC\!5J@#Q[ M3/V=/"ULJM?W^HWL@Z@.L2'\ "?_ !ZNDMO@QX M0,>'TD(_BEN)7S^!;%=[ M10!QW_"JO N,?\(S9?D?\:J7/P9\ 70.[P^D9/>*XE3'Y-BN\HH \?U+]G7P MK=!C87VI63]AO65!^!&?UK@M=_9V\2V"M)I%]9ZH@Z(?W$A_!LK_ ./5].T4 M ?"6L>']7\/W7V;5]-N;*7L)HRH;W!Z$>XK-K[VO].LM4LWM-0M(+JV?[T4T M8=3^!KQCQI^SW87JR7GA2?[%<=?L<[%HF]E;DK^.1]* /G"BM#6M#U/P]J4F MGZM92VETG5)!U'J#T(]QQ6?0!U/@GQ_K?@74?M&FS;[5S^_LY"?+E'T[-Z,. M?J.*^L/!7CG1_'.DB\TV7;,@ N+5S^\A;W]1Z$<'ZY ^)JU?#WB+4_"VLPZK MI-R8+F(_577NK#NI]* /NJBN1^'WC_3O'NB"ZM\0WT("W=H3DQMZCU4]C_45 MUU !1110!E^)?^15UC_KRF_] -?"E?=?B7_D5=8_Z\IO_0#7PI0 4H)!R#S2 M44 ?2?P<^+@UA(?#7B&X_P")BH"6EU(?^/@=D8_W_0_Q?7K[97P"K,CJZ,59 M3D$'!!KZ<^#_ ,6E\1PQ>']>F"ZQ&N()W./M2CL?]L#\^O7- 'L5%%% !111 M0 4444 %%%% !1110 4444 %%%% !7Q)\0?^2C>)/^PGNF?\@JS_P"N"?\ H(JU573/^059_P#7!/\ MT$5:H **** "OA7Q/J7]L^*M6U+=D75Y+*I_V2Q(_3%?9WC+4O['\%:WJ ;: MT%E*R'_;VD+^N*^'* "BBB@ HHHH *]8^ ?BK^Q?&K:1/)MM-641C)X$RY*' M\?F7ZD5Y/4MMD? O4_[/^*=A&6VI M>12VS'ZKN'_CR"OK>OA?PMJ7]C>+-(U(MA;6\BE;_=# G],U]T4 %%%% !11 M10!\$7__ "$+G_KJW\S5>K%__P A"Y_ZZM_,U7H GL;22_O[:SB*B2XE6)"Q MX!8@#/MS7J__ SGXQ_Y_P#1/^_\O_QNO-?#7_(U:1_U^P_^ABONN@#Y>_X9 MS\8_\_\ HG_?^7_XW1_PSGXQ_P"?_1/^_P#+_P#&Z^H:* /E[_AG/QC_ ,_^ MB?\ ?^7_ .-T?\,Y^,?^?_1/^_\ +_\ &Z^H:* /E[_AG/QC_P _^B?]_P"7 M_P"-T?\ #.?C'_G_ -$_[_R__&Z^H:* /E[_ (9S\8_\_P#HG_?^7_XW1_PS MGXQ_Y_\ 1/\ O_+_ /&Z^H:* /E[_AG/QC_S_P"B?]_Y?_C=>J?!_P"'FK^ M+?5X]6GLI3>/$8_LKLV-H;.=RC^\*]-HH *^-/BU_P E4\0?]? _] 6OLNOC M3XM?\E4\0?\ 7P/_ $!: .+HHHH ]4TWX ^+-4TNTU""]T=8;J%)T#S2!@K* M&&<1]<&K7_#.?C'_ )_]$_[_ ,O_ ,;KZ'\'_P#(DZ!_V#K?_P!%K6U0!\NG M]G/QB!_Q_:*?^V\O_P ;J"7]GOQM&/E;3)?]RY/]5%?5-% 'R%=?!'Q_:@D: M*LRCO#=1']"P/Z5S6I>"O%&D M?^']2@0=9&MFV?]] 8_6ON*B@#X HK[BUO MP7X:\1*PU;1+.Y=NLIC"R?\ ?8PP_.O*?$W[.=A<*\_AK4I+67J+:\^>,^P< M#TN([B MVFDAGC8,DD;%64CN".0:]^^&_P =_-:'2/&$BJQPD6I8P#Z"4=O]X?CW-?/E M% 'WZCK(BNC!D8 JRG((]13J^6?A3\7KCPI-%HVMR//H;G:CG+-:$]QZIZKV MZCT/U%;W$-U;QW%O*DL,JAXY$;*LI&00>XH DHHHH **** "BBB@#@?C5_R2 M+7?I!_Z/CKX^K[!^-7_)(M=^D'_H^.OCZ@ HHHH **** "BBB@ KK? ?P_U; MQYJWV:R7R;.(C[3>.N4B'I[L>P_D.:L_#GX<:CX^U7:FZWTN!A]JN\=/]A?5 MC^G4]@?K?0M"TWPWI$&EZ5;+;VL(P%'4GNS'N3W- %7PKX3TGP=HR:9I%OY< M8YDE;EYF_O,>Y_0=JW*** "BBB@ IDLL<$+RRN$C12S,QP% Y)-/KSOXVZ^V MA?#2^2)]L^H,MDA'HV2__CBL/QH ^:?'OBJ7QEXQOM7 MI]R:YJBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** -+P]_P C M+I7_ %^0_P#H8K[MKX2\/?\ (RZ5_P!?D/\ Z&*^[: "BBB@ HHHH 9)(D,3 MRR,%1%+,QZ #J:^'/%NN/XE\6:IK+D_Z5<,Z ]53H@_!0!^%?5_QE\5>+--T6+(^U3!9&'5(QR[ M?@H)K[?MK:&SM(;6WC$<$*+'&B]%4# _ 5\^_LW^'A+>ZMXBE3(A46D!(_B M;#/^( 3_ +Z-?0] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %8_BCQ+I_A+0+G6-2DVPPCY4'WI'/1%]S_P#7Z"M,_$K6UG*3HU@Q2W /$K=&D_'H/;ZF@#E?%OBK4?&7B"?5] M2DR[_+'$#\L*#HB^P_4Y/>L.BB@ KL_A_P##C5O'NHE;8&VTZ)@+B]=Y]2>I)Y)H S?"?@W1?!FEBQT>U$><>;._,DQ]6;O].@["M^B MB@ HHHH **** "BBB@ HHHH **** ,+Q3X0T;QCI;6&L6BRJ,F.5>)(F]4;M M_(]P:^4_B%\-=6\!7X\[-UIJ:79:UIL^G:C M;)U 'P917>?$[X;W?@+6 8R\^CW+'[+<$$->@U?3)=LT9PZ'[LJ'JC#N#_@>HK[+\)^*-/\8>'K;6 M-.?,/W\$^)UCNI3_ &/?,([I3TC/\,@^ MF>?;/M0!]>T4BLKJ&5@RL,@@Y!%+0!E^)?\ D5=8_P"O*;_T U\*5]U^)?\ MD5=8_P"O*;_T U\*4 %%%*JECA02>N * $I\4LD$R30R-'+&P9'0X*D<@@]C M3** /J?X1?%>/Q;;)HNLRJFN0I\CG@7:@=1_M@=1WZCN!ZQ7P+;7,]GOGZ@ HHHH [%_ \Q^%,/C&/>Q%^\$R]A%A55O\ OL,#_O#TKCJ^ MP_!7A:VN/@QIF@7B?N;S3LRC'(,N7S]06S]17R5K.E7.AZU>:5>+MN+29HG] M"0<9'L>H]C0!1HHHH ]Z_9S\5>7<:AX6N)/ED'VNU!/\0P'4?4;3^#5]"U\* M>&]$_#OAF_N-XGU6WDEF1ND9!!4>QVNN??-+\+O"G_ M E_CNQL98]UG"?M-WQQY:D<'_>.%_&O;?VB=,^T^ [.^5?FL[U&O\ D:M(_P"OV'_T,5]UU\*>&O\ D:M(_P"OV'_T,5]UT %% M%% !1110 4444 %%%% !1110 5\:?%K_ )*IX@_Z^!_Z M?9=?&GQ:_Y*IX@ M_P"O@?\ H"T <71110!]R^#_ /D2= _[!UO_ .BUK:K%\'_\B3H'_8.M_P#T M6M;5 !1110 4444 %%%% %:_T^SU6RELM0M8;JVE&'BF0,I_ U\\_$;X$3:: MDNK>$EDN+5L9ZL/8\_6OH^B@#X!(()!&".H-)7TU\6_@]%KT4^ MO^'8%CU907GMD&%NO4@=G_\ 0OKU^9W1HW*.I5E."",$&@!M>Q_!?XHMX?O( MO#>M3_\ $IN'Q;S.>+:0GH3V0G\CSW->.44 ??\ 17D/P,^(+>(M%/A_4IMV MIZ?&/*=CS-!T!]RO /L1[UZ]0 4444 %%%% ' _&K_DD6N_2#_T?'7Q]7V#\ M:O\ DD6N_2#_ -'QU\?4 %%%% !1110 5VGPY^'E_P"/M:\F/=!IL!!N[K'W M1_=7U8_IU/O0\#^"]0\<^(8M,L1LC'SW-P1E88^Y/J>P'<_B1]B^'?#NG>%M M$M])TN 16T(Z_P 3MW9CW)_SQ0!+HNBZ?X>TFWTO2[=;>T@7:B+^I)[D]2>] M:%%% !1110 4444 %> _M+WK"/P[8@_*QGF8>XV!?YM7OU?/7[2\#"[\.7&# ML9)TSZ$%#_7]* /!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MKH/"O@K7O&5]]FT:Q:55.))W^6*+_>;M].OH*^D_ 7P8T/P@8KZ^VZGJZ\B: M1?W<1_V%/?\ VCSZ8H \O^&7P7U;5KRTUS7!)IMA%(LT41&)I\$$<'[J^YY/ M81@BCU).!0!]@?!S1 MAHWPOTA2N);M#=R'U\PY4_\ ?.T?A7=U7L;2.PT^VLXO]7;Q+$OT4 #^56* M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHI&8* MI9B H&23VH \J^.OC8^'/"@T>SEVZAJH:,E3S'#_ !G\<[1]6]*^5JZKXB^* MF\8>-]0U0,3;!O)M0>T2\+^?+?5C7*T %;'A?PW?>+?$5IHVGKF:=OF18U+5%#C<.8X.JK^/WC_P'TH ] \,^'-/ M\)Z!;:/IL>V"!>6/WI&[NWJ2?\.@K7HHH **** "BBB@ HHHH **** "BBB@ M HHHH **** ,OQ%X?T_Q1H5UI&I1>9;7"XR/O(W9E/8@\BOB_P 6^&+[P?XD MNM&OQEX6S'(!@2QG[KCV(_(Y':ON2O+OC?X'7Q-X3;5;2+.IZ6IE7 YDAZNG MOC[P^A'>@#Y1HHHH ^H_@-XU.O\ AA]"O)=U]I:A8RQY> \+_P!\_=^FVO7* M^)? /BA_!_C/3]7!;R$?R[E1_%$W#?7 Y'N!7VPCI+&LB,&1@&5@<@@]Z ,W MQ+_R*NL?]>4W_H!KX4K[K\2_\BKK'_7E-_Z :^%* "NM^&"J_P 3/#ZLH96N MU!!&01S7)5UWPN_Y*?X=_P"OQ?ZT =K\8?A*WAV67Q#H$!.D2-FXMT&?LK'N M/]@_I]*\*5%>-U*LC#(8'J".XKY=^+OPGD\*7+ZWHL3/HDK?O( MQR;1CV/^P>Q[=#VR >2U8LKVYTV]AO;*=X+F!P\BU\%Z9J5YH^I6^H:?.5 M#RI_P]N]?6_PR^)5GX]TG9)L@UFW4?:;8'AA_P ]$]5/Z'CT) .]HHHH *** M* "BBB@ HHHH **** "OB3X@_P#)1O$G_83N/_1AK[;KXD^(/_)1O$G_ &$[ MC_T8: .;HHHH ^]=,_Y!5G_UP3_T$5:JKIG_ ""K/_K@G_H(JU0 4444 ?*' MQ]U/[=\3IK8-E;&UB@Q[D&0_^A_I7E];_CC4_P"V/'6N7X;-HY8G*.C#!5@<$'\:CH *^G/V>_%7]J>%;C0+B3-QIC[HLGDPN21^3;A] M"M?,===\,_%)\(>.]/U%WVVCM]GNN>/*?@D_0X;_ (#0!]HT4@((R#Q2T %% M%% !1110 4444 %%%9?B/6[?PWX M*O[3\46_A^WDS;Z8FZ;!X,S@']%Q^):O&ZLZA?W&J:EK,'7(Y6% M&SM8;:WC6."%!'&B]%4# _"BZMX[NTFMI1F.9&C<>H(P: /@6BI[VUDL;ZX MM)>)()6B<>ZD@_RJ"@ KZ#_9JU/,&OZ4S?=:*Y0?4%6_DE?/E>I? #4_L/Q, MCMBV%OK66#'N )!_Z : /JVBBB@ HHHH ^"+_P#Y"%S_ -=6_F:KU8O_ /D( M7/\ UU;^9JO0!J>&O^1JTC_K]A_]#%?==?"GAK_D:M(_Z_8?_0Q7W70 4444 M %%%% !1110 4444 %%%% !7QI\6O^2J>(/^O@?^@+7V77QI\6O^2J>(/^O@ M?^@+0!Q=%%% 'W+X/_Y$G0/^P=;_ /HM:VJQ?!__ ").@?\ 8.M__1:UM4 % M%%% !1110 4444 %%%% !7S_ /'7X:*JR^,-'@ YSJ,*#U_Y:@?^A?GZFOH" MHYX8KF"2">-9(9%*.CC(92,$$>F* /@2BNP^)7@U_!'C&YT] QL9?W]FYYS$ M2>,^JG(_#/>N/H U?#>OW?A?Q%9:S8MB:UD#;J6+[[:ZB66,]\$=#[CH?<5\'5]&?LZ>*3P8@_P# S0![G1110 4444 <#\:O^21:[](/_1\=?'U?8/QJ_P"21:[](/\ MT?'7Q]0 4444 %7M&TB]U_6+72].A,UW_C!56'-O">0OLQX)_ =C0!V'@/P58^!?#D6FVH$EPV'NKG&#-)Z M_0= .P]R374444 %%%% !1110 4444 %>6_'O0'UCX>->PINFTR9;@X'/EGY M7_F&_P" UZE45S;PWEK-;7$:R03(8Y$89#*1@@_@: /@6BNJ^(7@RY\#^*KC M39 S6CDR6DQ_Y:1$\<^HZ'W'N*Y6@ HHHH **** "BBB@ HHHH **** "BM; M0?#&M^)[K[-HNF7%Y(#AC&ORI_O,>%_$U[9X2_9U13'=>*[_ 'GK]BLS@?1I M#S^"C\: /#=&T/5/$%^MEI%A/>7#?P1+G ]2>@'N>*]V\%?L\Q0F.]\77 F; M@BPMG(4>SOU/T7'U->T:-H6E>'K%;+2+""SMQ_!$N-Q]2>I/N>:T: *UAI]G MI=E'9V%K#;6T0PD4*!57\!5FBB@ HHHH **** "BBB@#Y"^-UQY_Q:U@9RL0 MAC'_ 'Z0G]2:\]KM/BV^_P"*GB _]/ 'Y(HKBZ "M[P/;"\\>^'[=AE9-1MP MP]O,7/Z5@UUWPO4-\3O#H/\ S^*?RYH ^T:*** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ K@OC'XB/AWX;Z@\3[+F]Q9PD'G+ MYW'_ +X#?CBN]KYS_:2UHRZSH^B(WRP0-=2 =V<[5S] A_[ZH \,HHHH ZSX M;>%O^$O\=:?ICINM5;S[K_KDG)'X\+_P*OM)5"*%4 *!@ #@"O#_ -G#P^+? M1=4\02I^\NI1;0DCD(G+$>Q8@?\ *]QH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ I" 001D'J*6B@#XQ^*'A4>$/'E_81)MLY3]IM1V$;YX M'T(9?^ UQU?2G[1OA\77AS3M>B3]Y93>1*0/^6;]"?HP _X%7S70 5]>?!7Q M$?$'PWLEE?=39RYZX7&P_]\%1]0:^0Z]M_9OUHV_B/5=%=ODN[<3H#_?C M.,#ZAS_WS0![]XE_Y%76/^O*;_T U\*5]U^)?^15UC_KRF_] -?"E !77?"[ M_DI_AW_K\7^M#+QM4TM'ET&=^.YM6/\ Q_N^A_ \\GR^OOB\L[; M4+.:SO($GMID*212#*LIZ@BOD_XJ?"ZY\#:@;VQ5YM"N'_=2'DP,?^6;G^1[ M_6@#S>KVCZQ?Z!JUOJ>F7#V]W;MN1U_4$=P>A'<51HH ^ROAQ\1+#Q]HWF)M M@U2 7=KG[I_O+ZJ?TZ'W[6OA/0->U'PSK-OJNEW!ANH#D'LP[JP[@]Q7U]\ M/_'VG>/=#%W;$0WL0"W=H6RT3>H]5/8_U% '74444 %%%% !1110 4444 %? M$GQ!_P"2C>)/^PG)/^PGIJ&Q)=-';+_P "<%O_ !T-0!\B$DDDG)/4TE%% !7LG[.6 MF_:/&FHZ@RY6TLB@/HSL,?HK5XW7TK^S=IOD>%=6U(KAKJ\$0/JL:@_SD- ' MM5%%% 'RM\>O"G]A^-1JUO'MM-64RG X688#C\Z?_ M *)/D\G:/D;\5QSZ@UZ#7RA\"O%7]@>.TT^>3;9ZLHMVR>!*.8S^9*_\#KZO MH **** "BBB@ HHHH *\%_:,\5>7;6'A:WD^:4_:[H _PC(13]3N/_ 5KW6Y MN8;.UFNKB01P0HTDCMT50,DG\!7Q#XO\13>*_%FHZU-D?:928U/\$8X1?P4" M@##HHHH *^B_V=?"GV?3KWQ3:%?%MJ17L0<_[!8*WZ$USU*"5(()!'((H ^_J* MSM U$:QX=TS4@0?M=K%/_P!]*#_6M&@ HHHH ^"+_P#Y"%S_ -=6_F:KU8O_ M /D(7/\ UU;^9JO0!J>&O^1JTC_K]A_]#%?==?"GAK_D:M(_Z_8?_0Q7W70 M4444 %%%% !1110 4444 %%%% !7QI\6O^2J>(/^O@?^@+7V77QI\6O^2J>( M/^O@?^@+0!Q=%%% 'W+X/_Y$G0/^P=;_ /HM:VJQ?!__ ").@?\ 8.M__1:U MM4 %%%% !1110 4444 %%%% !1110!Y?\=?"@U_P))J,,>;S22;A2!R8O^6@ M^F,-_P !KY0K[[GACN8)()D#Q2*4=6Z,I&"#7PUXFT9_#WB?4](?)-I!HH W**** .!^-7_)(M=^D'_H^.OC MZOL'XU?\DBUWZ0?^CXZ^/J "BBI[.TGO[V"SM8VEN)Y%BB1>K,QP!^9H ]+^ M"/@,>*?$W]JWT6[2M,8.P8<2S=53W ^\?P'>OJVN?\%>%[?P=X3L=&@VLT2; MIY /]9*>6;\^GL .U=!0 4444 %%%% !1110 4444 %%%% '+^._ ^G>._#[ MZ?>?N[A,O:W(&6A?U]P>A'?Z@$?(7BCPIJ_A#5WTW5[4Q2#)CD'*2K_>1NX_ M4=\&ON6LW6] TKQ)IS6&L6,-Y;-SMD'*GU4CE3[@@T ?"5%?0?B3]G".1WF\ M-:OY0/(MKX$@?211G'U4_6O/-1^"GCS3V;&C"ZC'_+2VG1P?PR&_2@#S^BNF MD^'?C.(D-X6U-)R GA?51G^_;,G\P* .7HKT&R^"?CZ]( MSHHMT/\ %/XMT:9OUVB@#Q*I(()KJ9(;> M)Y97.%2-2S,?8#K7U)HW[/O@_3RKW[7NIR#J)9?+3\DP?S)KT32/#NC:!#Y6 MDZ7:62XP?(B"EOJ1R?QH ^6?#OP2\9Z]LDEL5TNV;_EI?'8V/]P9;/U KU_P MS^S_ .&-(*3:O+-K%P.=LG[N$'_AOXD_P"^ MF _K7+5H:#>C3?$6F7Y.!;7<4V?3:X/]* /N^BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH *^.?C!J1U/XIZW(&RD,JVZCTV M*%/_ (\#^=?8U?"GB2[-_P"*=7O"]FE)_WG)_K0!ET45-:6[7=Y!;)]Z: M18Q]2<4 ?9_PUTD:+\.-!L]NU_LBS./]J3YV_5C754R*)(84BC&U$4*H] .! M3Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .;^(&DC7/ MA_KMAMW,]H[QCU=!O7_QY17Q)7W\RAU*L 5(P0>]?!>I6AL-5O+,];>=XO\ MOEB/Z4 5:[/X3ZD=+^*.@S;L++T6[-AKNGW@.#!;_[0['N/Q X M"OO+5M)L==TJXTS4K=+BTN%V21OW]QZ$=0>QKY$^)/PYOO .L;?GGTJX8_9; MK'7_ &&]&'Z]1W .(K7\->)=3\)ZY!JVE3>7/$<%3RLB]T8=P?_ *XY%9%% M 'VQX&\;Z9XZT)-0L6\N=,+,=,\;:#'J>FR8/W9X&/SPOW5OZ'N* .AHHHH M **** "BBB@ KXD^(/\ R4;Q)_V$[C_T8:^VZ^)/B#_R4;Q)_P!A.X_]&&@# MFZ*** /O73/^059_]<$_]!%6JJZ9_P @JS_ZX)_Z"*M4 %>%_M*:GY>C:'I0 M;_77$EPP_P!Q0H_]&'\J]TKY;_:&U/[7\0H;)6^6RLD0CT9B7/Z%: /)**** M "OL7X/:9_9?PLT1"N'GC:Y8^N]BP_\ '2M?'L<;S2I%&I9W8*H'?%WPI_PBGCZ\BACVV5[_I=M@< M,3N4?1LC'IBOL.O+?CMX4_M_P,VI01[KS229Q@9-$!.H_AE7AQ^8./8BOB M&O/[ZXB MDWV5J?LMM@\%$)RP^K;C]"*X>@ HHJ2""6ZN(K>!&DFE<(B*,EF)P /QH ]M M_9V\*?:]6O/%%Q'F*S!M[4D=96'S$?13C_@=?1U<_P""?#47A'PAIVC1[2\$ M0,SC^.4\N?S)Q[8KH* "BBB@#Q/]I+3?.\,:/J87)MKMH2?02+G^<8KYLK[$ M^,FF_P!I_"S65"Y>!$N%]MC@G_QW=7QW0 4444 ?7WP4U/\ M+X6:4&;,EJ9 M+9_;:YV_^.E:]!KPW]FO4_,T/7-++?ZBYCN%'^^NT_\ HL?G7N5 !1110!\$ M7_\ R$+G_KJW\S5>K%__ ,A"Y_ZZM_,U7H GL[J2QO8+N''FP2+*F1D;E.1_ M*O2_^&@/''_/33__ &_^O7EM% 'J7_#0'CC_GII_P#X#?\ UZ/^&@/''_/3 M3_\ P&_^O7EM% 'J7_#0'CC_ )Z:?_X#?_7H_P"&@/''_/33_P#P&_\ KUY; M10!ZE_PT!XX_YZ:?_P" W_UZ/^&@/''_ #TT_P#\!O\ Z]>6T4 >I?\ #0'C MC_GII_\ X#?_ %Z/^&@/''_/33__ &_^O7EM% 'J7_#0'CC_GII_P#X#?\ MUZ^C_!6K76N^"](U6]*&YNK999"BX&X^@KX>K[3^&/\ R3+P[_UY)0!UE?&G MQ:_Y*IX@_P"O@?\ H"U]EU\:?%K_ )*IX@_Z^!_Z M '%T444 ?HN%O[2.5CZNN4/Z*OYU]45X'^TO9@P>';X#E6GA8^ MN0A'\C^= 'SY1110!]8? /4/MGPOMX2V39W4T'YD2?\ M2BO(_AIXMET'PY< M6J2;0]VTF,^J(/Z44 ?5=%%% ' _&K_DD6N_2#_T?'7Q]7V#\:O^21:[](/_ M $?'7Q]0 5[#^SYX5&J^+)]>N(\V^EIB+(X,S@@?DNX_4K7CU?87P<\/C0/A MIIBLFV>]!O9N.I?!7_QP(* .]HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M#YI_:1T\P^+=)U #"W%D8OJR.2?T<5XM7TW^T9I)NO!NGZFJY:QN]K'T21<' M_P >5/SKYDH **** /N+P9JHUOP5HNI;MS3V<;.?]O: W_CP-;M>0_L\ZZ-0 M\"SZ4[YETVY(5?2.3YA_X]O_ "KUZ@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH "<#)Z5\!.Q>1G/5B2:^_:^ Y8S%,\;#!1BI_ M"@!E;/A*,2^,]"C(R'U"W4CZR+6-6MX6E%OXNT68]([^!C^$BF@#[IHHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^'O'$8B\?^(X MP,!=4N0/IYK5]PU\.>-)1/XZ\0S#I)J5RP_&5C0!AT44H!)P.2: /N;7G\SP M;J;]=VGRG_R&:^&*^Z-?3R_!^J)_=L)1_P"0S7PO0 5UWPN_Y*?X=_Z_%_K7 M(UUWPN_Y*?X=_P"OQ?ZT ?:-%%% !1110 5G:YH>G^(]'N-*U2W6>TG7#*>H M/9@>Q'4&M&B@#XP^(7P_U#P%K9MI]TVGS$FTN\<2+Z'T8=Q^/2N/K[J\1^'- M-\5:)/I.JP"6VE'7HR-V93V(_P \5\?>// NI>!-=:QO 9+:3+6MTHPLR?T8 M=QV^A!H Y:NB\%^,]3\$:]'J>G/N4X6XMV/R3I_=/OZ'L:YVB@#[D\*^*M,\ M8Z%#JVER[HGX>-OOQ/W5AV(_7J.*VZ^*? GCG4O FNK?V1,EM)A;JU9L+,G] M&'8]OH2#]@>'/$>F^*M$@U;2IQ+;RCD'AHV[JP[$?YXH UJ*** "BBB@ KXD M^(/_ "4;Q)_V$[C_ -&&OMNOB3X@_P#)1O$G_83N/_1AH YNBBB@#[UTS_D% M6?\ UP3_ -!%6JJZ9_R"K/\ ZX)_Z"*M4 %?%7Q)U/\ M?XD:_=AMR_;'B4^ MJQ_(/T45]EZG?)IFDWE_)_J[6!YFSZ*I)_E7P;-*\\TDTC%GD8LQ/)(X]50[V_137VO7RQ^SWIOVSXC/>,ORV-G)(# MZ,Q"#]&;\J^IZ "BBB@ IDL4<\3Q2HKQNI5E89# \$>4 ?$?COPQ)X0\9Z MCHY#>3')OMV/\43%/MVAVGB:WCS-8GR+@@=8F/RD_1 MC_X^:^;* "M#0]7N= UVQU:T.)[2995&>#@\@^Q&0?K6?10!]YZ5J=MK.D6> MIV;[K>ZA6:,^S#//O5RO%/V=_%7V[P_=^&[B3,U@WG6X)ZPN>0/HW_H8KVN@ M HHHH *XCXL>*O\ A$_ -]0[@Y8?1=Q^H%=O7RS\??%7]M> M-$T>"3-KI*>6V#P9FP7/X#:OU!H \FHHHH *]7^ GA3^W/&IU>XCW6FDJ)1D M<-,M>45]D_"GPI_P (CX"LK66/9>W(^U761R'8#Y3_ +J[1]0: M .VHHHH **** *6KV"ZKHM_ISXVW=O) <^C*5_K7P>Z-'(T;J5=20P/8BOOV MOB;XAZ;_ &1\0]?LPNU5O9'0>BN=Z_HPH YFBBB@#US]GC4_LGQ N+)F^6]L MG4#U=2&'Z!J^HZ^*_AGJ?]D_$KP_=%MJ_:UA8^BR?NS^C&OM2@ HHHH ^"+_ M /Y"%S_UU;^9JO5B_P#^0A<_]=6_F:KT %%:GAOGQ3I /3[;#_Z&*^Y_(A_Y MY1_]\B@#X$HK[[\B'_GE'_WR*/(A_P">4?\ WR* /@2BOOOR(?\ GE'_ -\B MCR(?^>4?_?(H ^!**^^_(A_YY1_]\BCR(?\ GE'_ -\B@#X$HK[[\B'_ )Y1 M_P#?(H\B'_GE'_WR* /@2OM/X8_\DR\._P#7DE=1Y$/_ #RC_P"^13P HP M!T H 6OC3XM?\E4\0?\ 7P/_ $!:^RZ^-/BU_P E4\0?]? _] 6@#BZ*** / MN7P?_P B3H'_ &#K?_T6M;58O@__ )$G0/\ L'6__HM:VJ "BBB@ HHHH ** M** "BBB@ HHHH *\7_:1C!\&Z3)CE=0V_G&_^%>T5XK^TE*!X2TB'NU\6_*- MA_6@#YJHHHH LV]V]O&45F )SQ14UEITMY"9$3< VW.?I10!]X4444 <#\:O M^21:[](/_1\=?'U?8/QJ_P"21:[](/\ T?'7Q]0!K,%'\Z^[X(8[:WC@B4+'&H1%'8 8 KXS^%ML+KXG^'HV&0+M9/^^ 6_I7VA M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110!SOCO0_^$D\#:QI03=)-;,8 MAZR+\R?^/**^(NE??]?&GQ5\-GPQ\0]3M539;7#_ &JWXXV/DX'L&W+_ ,!H M XNBBB@#TOX'>)1H'Q#@M9GVVNJ)]E?)X#DYC/UW#;_P*OK2O@..1X94EB=D MD1@RLIP01T(K[6\ >*H_&7@VQU96'GLOEW*#^"9>&'X]1[$4 =-1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5\+^*K0V'B_6K,C' MD7T\?Y.17W17Q]\:-,.F?%/5P%Q'[B_P!7/$LJ_1@"/YU/7$?"+6!K7PQT:4MF2WB^RR#N M#&=H_P#'0I_&NWH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH CN)TMK:6>4XCB0NQ] !DU\%75PUW>3W+_?FD:1OJ3FOL?XJZP-$^&FN7 M.[;)+;FVC]=TGR%M,\8:%-I.JP[XGY21?OQ/V=3V(_7H>#6U1 M0!\1^-?!FI^!]>DTW44W(#],\:Z#)I>IQ] M?FAG4?/"_9E_J.XKX]\7>$M3\&:[+I6IQ89?FBE4?),G9E/I_(\4 85=A\/? MB!J'@+6QUG7* ML.H/=2.Q'0BM&OC?X;?$:^\ ZQN&^?2KA@+JUSU_VU]&'Z]#V(^N](U:QUW2 MK?4]-N$N+2X7?'(O?V/H1T(Z@T 7:*** "OB3X@_\E&\2?\ 83N/_1AK[;KX MD^(/_)1O$G_83N/_ $8: .;HHHH ^]=,_P"059_]<$_]!%6JJZ9_R"K/_K@G M_H(JU0!P_P 8-3_LOX6:W(&P\T2VRCU\Q@I_\=)KXXKZ6_:0U/R/">DZ:&PU MU>&4CU6-2#^KK7S30 4444 ?1/[-6F[-,U[52O\ K9H[=3Z;5+-_Z&OY5[M7 MG/P-TS^SOA9I[E22W+#ZL5'_CJK7HU !1110 4444 4]5TVVUG2;O3;Q- M]M=1-#(/9ACCWKX=U_1KGP]K]]I%V,3VDS1,<8#8/##V(P1[&ONZOGC]HOPI MY-Y8^*;:/Y9@+6[('\8&48_49'_ 10!X/1110!U'P]\4-X0\;Z=JQ8BW63RK MD#O$W#?7'WA[@5]K*RNBNC!E89!!R"*^ :^M_@EXJ_X2/P!!;32;KW2R+67) MY* ?NV_[YX^JF@#TBBBB@#$\7>(8?"OA34=:FP?LT),:G^.0\(OXL0*^(+FY MFO+N:ZN)#)/,[22.W5F)R2?Q->Z_M&>*O,N+#PM;R?+&/M=T ?XCD(I^@W'' MNM>"T %%%% '>_"#PI_PE7CZT2:/=8V/^EW.1P0I&U?Q;''IFOL*O+_@7X3_ M .$>\"IJ$\>V\U8BX;(Y$7_+,?D2W_ J]0H **** "BBB@ KY6_:#TW[%\2! M=A?EOK..4GU9WGCGB;;)&P=3Z$'(K[QTZ]34M+M+Z+_5W,*3+]&4$?SKX*K[(^$.I M_P!J?"W0Y2V7AA-LP]/+8H/T H [>BBB@#X(O_\ D(7/_75OYFJ]6+__ )"% MS_UU;^9JO0!J>&O^1JTC_K]A_P#0Q7W77PIX:_Y&K2/^OV'_ -#%?== !111 M0 4444 %%%% !1110 4444 %?&GQ:_Y*IX@_Z^!_Z M?9=?&GQ:_Y*IX@_Z^ M!_Z M '%T444 ?T]3RJS3./J45?Y-7T'7R M5\==8&J_$Z[A1MT=A#':@]L@;V_5R/PH \UHHHH ]H^$7@U_$/A.ZNPN0E\\ M?Y)&?ZT5ZC\#=-.G_"S3W9=KW%[?Q!;1YN-,;;-@#O%E]HT^XK$^Z"0C_6 M1'E6_+K[@CM7/T %>J? [QR/#/BDZ3>R[=-U0A"6/$4W1&]@?NGZ@]J\KHH M^_Z*\N^#'Q$7Q;H(TK49LZS8( Q8\SQ#@/[D< ^^#WKU&@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ KYZ_:3T0K=Z+KJ+PZ-9RMZ$'> MG\W_ "KZ%KC/BIX;/B?X>:G9Q)ONH4^TVXQSO3G ]R-R_P# J /C.BBB@#WK M]F_Q&$N-5\-S/CS +RW!]1A7'UQL/X&OH6OAGPIX@G\*^*=/UJWR6M90S*#] M]#PR_BI(_&OMZPOK?4]/MK^TD$MM<1K+$XZ,K#(/ZT 6**** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHJ&\NX+"RGO+J18K>"-I9';HJJ,DG\!0 M!X-^TAXB&W2O#<+\Y-Y< =NJH/\ T,_E7S_6[XQ\1S>+/%FHZU-N N)28T/\ M$8X1?P4#\Z_LVZ(9-5UG777Y885M8R>Y8[F_(*O\ WU7A5?8_PC\. M'PS\.=-@E39=70-W..^Y\$ ^X7:/PH Z3Q+_ ,BKK'_7E-_Z :^%*^Z_$O\ MR*NL?]>4W_H!KX4H *Z[X7?\E/\ #O\ U^+_ %KD:Z[X7?\ )3_#O_7XO]: M/M&BBB@ HHHH **** "BBB@ KF?&_@G3/'.A/IU^NR5)_#.I^$M1 M:W0&6B;^JGN/Z@5\?^(/#^I>&-:GTK5;X/8T 9E M=_\ ##XF7G@/5?*G+SZ+<,/M%N.2A_YZ)_M#N.X_ C@** /O73M1L]6T^"_L M+A+BUG0/%*AR&!_ST[5:KY(^%7Q1N? ^H"ROF>;0KA_WL8Y,#'_EH@_F._UK MZPL[RWU"SAO+29)[:9 \A!H GKXD^(/\ R4;Q)_V$[C_T8:^VZ^)/ MB#_R4;Q)_P!A.X_]&&@#FZ*** /O73/^059_]<$_]!%6JJZ9_P @JS_ZX)_Z M"*M4 ?,O[1NI_:/&>G:1"A!/YM@?0-0!\\>)-)]0;RK< MDSQQI%&L<:A$0!551@ #H!3J** "BBB@ HHHH *\W^. MFF_VA\+;Z0+N>SEBN5'T;:?_ !US7I%8_BO3?[9\(ZQIH7+7-G+&H_VBIQ^N M* /ABBBB@ KZ7_9PU/S_ CJFFELM:W@D ]%D48_5&KYHKV;]G'4_L_C'4]. M9L+=V?F >K1L,?H[4 ?3-%%% 'P1?_\ (0N?^NK?S-5ZL7__ "$+G_KJW\S5 M>@#4\-?\C5I'_7[#_P"ABONNOA3PU_R-6D?]?L/_ *&*^ZZ "BBB@ HHHH * M*** "BBB@ HHHH *^-/BU_R53Q!_U\#_ - 6OLNOC3XM?\E4\0?]? _] 6@# MBZ*** /N7P?_ ,B3H'_8.M__ $6M;58O@_\ Y$G0/^P=;_\ HM:VJ "BBB@ MHHHH **** "BBB@ HHHH I:MJ=OHVCWFIW;;;>TA::3Z*,X'O7POJ=_/JNJ7 M>HW)W3W4SS2'_:8DG^=?1'[0WBX6.B6WA>VD_P!(OB)KD _=A4_*#_O,/_'# MZU\VT %/AADN)XX8E+R2,$11U))P!3*]"^"_AT^(/B18,Z;K;3\WDI[97[@_ M[[*_@#0!]6:#I::)X>T[2D(*V=M'!D=]J@9_'&:*T:* "BBB@#@?C5_R2+7? MI!_Z/CKX^K[!^-7_ "2+7?I!_P"CXZ^/J "OLWX6>)%\3_#S2[MGW7$$?V6X MYR?,08R?%K W4G07=V"D?U5/O'\=OTH ]PFFBMXS)-*D:# +.P &>.IJ2OBYO&&O\ MBSQ=I4VM:G-6?&[P&? M%/AH:K81;M4TQ2X"CF6'JR>Y'WA^([U\IU]_U\L?&OX"/'6D^.M'%[ITFR= !A[_ %R! MT] !1110 4444 %%%% !1110 4444 %%%% !1110 445A^*O%ND>#M'?4=7N M1&G(CB7F29O[J#N?T'?% &R\L<90/(JF1MJ!CC<<$X'J< G\*?7S3X6^(&J^ M/?CCH-S>'R;**286UFC96(>2_)]6/<_R'%?2U 'QM\5O"1\(^.[VVBCVV-R? MM-I@[4].W3VX YD7'SQ_B "/=1Z MU\BT %?0O[/WCM9;=_!^H2_O(]TM@S'[R]7C_#EA[%O2OGJK%C>W.FWT%[9S M-#.;&QDC+64)^T79 MQQY:D<'_ 'CA?QK[. P,"O-/@KX(/A/P@+R\BVZGJ>V:4,.8X\?(GY$D^YQV MKTN@#+\2_P#(JZQ_UY3?^@&OA2ONOQ+_ ,BKK'_7E-_Z :^%* "NN^%W_)3_ M [_ -?B_P!:Y&NN^%W_ "4_P[_U^+_6@#[1HHHH **** "BBB@ HHHH *** M* "N,^(OP\T_Q]HIADVP:E ";2[QRA_NMZJ>_IU%=G10!\'ZUHNH>'M7N-+U M.W:"[@;:Z-^A![@]0:H5]B_$OX;V7CW2,KL@U>W4_9;DCKWV/ZJ?T/([@_(V MJ:7>Z+J=QIVHV[V]W;OLDC<<@_U'<'N* *=>H_"7XJS>#+Q=*U61Y="G?GN; M5C_$H_N^H_$>&ZMX[BWE26&50\) M/^PG3:,3U_W">H[=1WSPWCV1)OB M#XBEB=7C?49V5U.0P+G!![B@#G:*** /O73/^059_P#7!/\ T$5+F? ?3?M_P 4;28KE;*WEN#_ M -\[!^KBO,Z]\_9JTW,^OZHR_=6*W0_4LS?R2@#Z#HHHH **** "BBB@ HHH MH X_XG^%!XO\"7]A&FZ\B7[1:<<^:@) '^\,K_P*OC$@@X/6OOZOD+XS>%/^ M$7\?730Q[;+4>'+F3$%^IF M@R>!*@Y'XK_Z *X/XE^*3XO\=ZAJ2/NM$;R+7T\I. 1]3EO^!5RL$\MM,LT$ MCQR+]UT."/QJ.@ HHHH T_#NB7/B3Q%8:/:#]]=S+&#C.T?Q,?8#)_"ON+3= M/M])TNUTZS39;6L2PQKZ*HP/Y5X-^SIX4WS7WBJYCX3-I:9'&]#N]7U&39;6T9=O5CV4>Y. /8?;J%]LGO@ '#^)_$-YXJ\1WNLWQ_?7,F MX)G(C7HJCV P*R*** "OJGX#>$SH/@HZK<1[;S5F$O(Y6$9V#\+M'72-3F']MV:8)8\W,8X#CU8IU\%:;J5YH^I6^ MH:?*5#RI_P ]N]?6/PS^*FG^.;);2Y,=KKD2_O;?.!+CJ\?J/4=1 M].: /1**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBL77?%WA_PS&7UG5[6T.,B-WS(P]D&6/X"@#:HKP[Q'^T=IMMOA\.Z7+>.. M!<79\N/ZA1\Q'UVUY%XE^*/B[Q3OCOM6DBMF_P"7:U_=1X]"!RP_WB: /IWQ M-\4?"/A3?'?:HDUTO_+K:?O9,^AQPI_WB*\8\4?M#ZWJ&^#P]9Q:9">!/+B6 M8^XS\J_D?K7C%% %S4M5U#6;QKS4[VXO+ANLD\A=OIST'M5.BB@#2\/?\C+I M7_7Y#_Z&*^[:^$O#W_(RZ5_U^0_^ABONV@ HHHH **** "BBB@ JEJVE66N: M5 M?:TFW2V,Q+6EUCB1?0^ MC#N/QZ$5R%?VNH^C+T8 M=U8="#Z&OJ3X=_/&<<=C>F/3]:QCR&;Y)CZQD_P#H)Y^O6ODFE!*L&4D$ M<@CM0!]_45\O^!OCQJ^@K'8^(4DU6P7"B;=_I$8^IX?\>?>OH+PUXRT#Q=:^ M?HVI17! R\.=LL?^\AY'UZ4 ;U%%% !1110 4444 %%%% !1110 45S7BGQ] MX;\'0EM7U&-)\96UC^>9_HHZ?4X'O7S[XW^.NN^(UDLM&5M(T]N"R-F>0>[# M[OT7\S0!Z_\ $'XPZ+X,26RM"FHZR!C[.C?)$?\ IHPZ?[HY^G6OE_Q)XGU; MQ9JSZEK%VT\[<*.B1K_=5>@'^3S622222OL.@ KY<^.'P\/AS6V\0:=#C2M0D)D51Q!,>2/ M96Y(]\CTKZCJEJ^DV6N:30>Q% 'P;176_$'P'?^ M ]?:RN-TME+E[2ZQQ*GH?1AQD?CT(KDJ -GPMXHU/PAKL&K:7-LFCX=#]R5. MZ,.X/^!'(KZ_\$>.=*\=:*M]I[A)T %S:LWSPMZ'U!['O]<@?$]:F@>(=4\, M:O%J>D73V]S'QDM>D4 %%%% !1110 4444 %%%% !1110 5S?C3QMI/@?16U#4I-T MC9%O;(?GG;T'MZGH/R!Y[XA?%W1O!4G]: )O%GBO4_&6O3:MJDNZ1_ECB7[ MD*=D4>@_4\UAT44 %>K?!/X>'Q1KHUK488>?%'X8VOCO3/M%L$@UNW3]Q.>!(/^>;^WH>Q]LUZ'10 M!\$W]A=:7?SV-] ]O=0.4EB<8*L.U5J^M/BM\+;?QO8'4-/5(==MT^1^@N%' M\#'U]#VZ=.GRC=6MQ8WJZ9_R"K/\ ZX)_Z"*^ M>?VD]3\WQ#HNEAN+>U>01[KW2B;F/ Y,>/WB_E\W_ $5Z73719$9'4,K M#!!&010!\!45U/Q#\+-X/\;ZAI04BV#^;:D]XFY7ZXY7ZJ:Y:@ HHHH *GLK M.?4;^WLK6,R7%Q(L42#JS,< ?F:@KV+]GWPI_:OBJ?7[B/-MI:XBR.&F8$#\ MER?J5H ^A?"N@0>%_"^GZ+;X*6L(1F ^^_5F_%B3^-;%%% !1110 4444 %% M%% !1110!\]?M*Z;MN]!U55^_'+;.?3:0R_^A-7@M?5?[0.F_;?AJ;H+\UC= MQ3$^BMF,_JXKY4H **** /M+X8ZG_:WPT\/W1;@#4\-?\C5I'_7[#_Z&*^ZZ^%/#7_(U:1_U^P_^ABONN@ HHHH **** M "BBB@ HHHH **** "OC3XM?\E4\0?\ 7P/_ $!:^RZ^-/BU_P E4\0?]? _ M] 6@#BZ*** /N7P?_P B3H'_ &#K?_T6M;58O@__ )$G0/\ L'6__HM:VJ " MBBB@ HHHH **** "HY[B&UMY+BXE2*&-2[R2,%50.I)/05SWBWQYX?\ !5H9 M=7O5$Q&8[6+#32?1?3W.![U\Q?$'XJZSXZE-LC@XFG&5:Z([>H3V[]_2O'Z** "I[.TN-0O(;.TA M>:YG<1QQH,EF)P *A52[!5!+$X R2:^GO@U\*_^$9MT\0:W"/[8F3]Q"P_X M]4([_P"V1U]!QW- '7?#7P+!X$\+1V9"/J$^);V9?XGQ]T'^ZO0?B>]=E110 M 4444 %%%% ' _&K_DD6N_2#_P!'QU\?5]@_&K_DD6N_2#_T?'7Q]0 4444 M%2VUS/9W,=S:S20SQ,'CDC8JRD="".AJ*B@#Z#\ ?'Z-DBTWQB-CC"IJ4:\- M_P!=%'3_ 'A^0ZU[K9WEKJ%I'=65Q%<6\HW)+$X96'L1P:^!ZWO#7C/Q!X1N M?.T74IK=2#^&OVCK:14A\2Z2\+]#J:'X^\*>(PHTS7;.61ND+/Y3_X[0![-17R_J_[1'BJ]#)IMI8:'O^1ETK_K\A_\ 0Q7W;7PEX>_Y&72O^OR'_P!#%?=M M !1110 4444 %%%% !1110 5D^(O#FE^*M'ETO5[99[:3D=F1NS*>Q'K_2M: MB@#XZ^(?PPU;P'>&5@UWI$C8AO%7@>BN/X6_0]NX'"U]\W5K;WUK+:W<$<]O M*I22*10RL#V(/6OGWXA? .:W,NI^#PTL7+/ISMEU_P"N;'[P_P!D\^A/2@#P MBBI)X)K:=X)XGBFC8J\K>&OC[XJT94AU-8=8MEX_?\ R2X]G'7ZD$UZKH?Q^\':F%2_:ZTJ M8]?/B+IGV9,_J!7RI10!]TZ9XHT#6@ITS6;"[+=%AN%9OQ&T^W9>L9G4O_WR#D_E7Q9>:WJVHC%] MJE[= ]I[AW_F:H4 ?4.N_M#>%M/#)I-M=ZI*.C!?)C/XM\W_ ([7E'B7XX^, M-?#PVURFDVK<;+,$.1[R'YL_3%>:T4 /EEDFE:65VDDT\3Z](;6X@#&WL5P6^92N9#VX8_*.?4CI7NU !1110!B^*/"^F>+]# MFTG58=\,G*.O#Q/V93V(_P#K'@U\A^.? >K>!-8-G?H9+:0DVUVB_),O]&'= M>WN,$_:U9VNZ%IOB329M,U:U2YM91RK=0>S*>H(]10!\(T5Z7\1?@_JW@R26 M_L!)J&B9SYZKEX!Z2 ?^A#CZ=*\TH 4$@@@D$<@BO5O!7QUU_P .K'9ZPIU> MP7@&1\3QCV?^+Z-^8KRBB@#[1\+_ !+\*^+51=/U...Z;_ETN<1R@^@!X;_@ M)-==7P!77:%\3O&/AU5CL=@#9P/IB@#[1HKYMTS]I+6H JZ MIH=C=XZM!(T)/Y[A72VW[2>AN!]KT+48CW\ITD_F5H ]MHKQ_P#X:/\ "./^ M0;KF?^N,7_QRJ=S^TGH2 _9="U&4]A*Z1_R+4 >V45\W:G^TEK,P8:7H5E:Y MZ-<2M,1^6VN!UWXH^,O$*M'>ZY<) W!AML0ICT(7&1]#>-?CQKOB!9+/1$.D6#<%T;,[CW;^' M_@//N:\EZT4 *S%V+,26)R23R32444 %=-X)\#:MXZUE;'3H]D*8-Q=./DA7 MU/J?0=_IDCH?AW\(=7\:RQWMV)+#1^,5]2Z!X?TSPQ MI$6F:3:I;VL?8=6/=F/4D^IH K>$_"FE^#="BTK2XML:_-)*WWYG[LQ[G^70 M5N444 %%%% &7XE_Y%76/^O*;_T U\*5]U^)?^15UC_KRF_] -?"E !77?"[ M_DI_AW_K\7^M5_%OX4Q>,+1]7TB-(]=A3D< 72C^$_P"T.Q_ \8(]4HH M^!)H9;:>2">-XIHV*/&ZX96'!!!Z&HZ^HOB]\)D\402:]H<*IK4:YEB7@7:C M_P!G'8]^A[5\ONCQ2-'(K(ZDJRL,$$=010 VBBB@#[UTS_D%6?\ UP3_ -!% M?)'QGU/^T_BIJY#9CMBELOMM0!O_ ![=7UMI[*FCVKL0%6W0DGL-HKX:UO4& MU?7M1U)L[KNYDG.?]IBW]: *%%%% &AH>G'5_$&FZ:H.;NZC@X_VF _K7WVU#M_\>*U]@4 %%%% !1110 44 M44 %%%% !1110!XS^T+X4_M+PU;^(K>/-QIK;)L#DPN?_96Q^#&OF:OO;4+" MWU33KFPNXQ);7,312H>ZL,']#7P]XET*X\,^)-0T:ZSYMI,8]V,;UZJWT*D' M\: ,JBBB@!54LP502Q. !U-?:7PW\*CP?X'T_3&0+=%?.NCZRMRP_#A?HHKY MT^"?A3_A)?'L%S/'NLM+ NI@ HHHH **** "BBB@ MHHHH **** .;^(&F_P!K_#[7K(+N9[*1D'JZCX MKX0UK3VTG7=0TUL[K2YD@.?]EBO]* *-%%% 'N'[-FI^5K^MZ66XN+9+@ ^L M;;3_ .C/TKZ/KY ^"VI_V;\5-)W-B.Y\RV?WW(=O_CP6OK^@#X(O_P#D(7/_ M %U;^9JO5B__ .0A<_\ 75OYFJ] &IX:_P"1JTC_ *_8?_0Q7W77P)!-);3Q MSPN4EC8.C#JK Y!KJO\ A:/CC_H9M0_[^4 ?:-%?%W_"T?''_0S:A_W\H_X6 MCXX_Z&;4/^_E 'VC17Q=_P +1\M M\ B,S9V9#YQ^0_*@#V2OC3XM?\E4\0?]? _] 6OLNOC3XM?\E4\0?]? _P#0 M%H XNBBB@#[E\'_\B3H'_8.M_P#T6M;5?%-M\2/&5I:Q6UOXCOHX(4$<:+)P MJ@8 'T J7_A:/CC_ *&;4/\ OY0!]HT5\6GXH>.",?\ "3ZA_P!_*@E^(GC. M88;Q3JX_W+MU_D: /MFLS4O$>B:.I.I:O8VF.HGN%0_D3FOB6[\0ZU?@B\UC M4+@'J)KEW_F:S: /K'6_CQX*TI66UN+C4YAQMM8B%S[LV!CW&:\H\3_'_P 3 M:PKP:1%%H]NW&Z,^9,1_OD8'X 'WKR6B@"6YN;B\N9+FZGDGGD.YY97+,Q]2 M3R:BHHH *D@@EN9XX((GEFD8*D:*69B>@ '4UL>&/"&M^,-2%EHUD\S CS)3 MQ'$/5FZ#^9[ U]0_#OX3Z1X&B6[DVWVLLN'NG7B//41CL/?J?8<4 &M[4X*VWN>Q?]!]>GLM%% !1110 4444 %%%% ' _&K_DD6 MN_2#_P!'QU\?5]@_&K_DD6N_2#_T?'7Q]0 4444 %%%% !1110 4444 ;>E^ M,?$NBA5TW7=0MD7I&EPVS_OG./TKK;'XZ>/+, 2:E!=J.T]JG\U ->;T4 >R MV_[1_B= !<:5I,ONB2(?_0S5^/\ :6U$#]YX;M6/^S'T4 >P7'[1OBV3(AT_1X1 MZ^5(Q_5\?I6-=_'3Q]A<)>P865?3)Z M,/8Y]L5\\>,/@IXH\+^9<6L7]K:>O/G6JDNH_P!J/J/PR/>OK:B@#X!(()!& M".QI*^T?%'PT\*>+B\FI:8B73?\ +W;_ +N7/J2.&_X$#7COB+]G+5+8O+X> MU2&]CZB"Z'E2?0,,J3]=M 'B%%;VM^"?$WAPL=6T2\MD7K*8RT?_ 'VN5_6L M&@ HHHH **** "BBB@ HHKZ*2^(-3@L8^I@MAYLGT)X4?4;J]C\+?#+PIX1V2:=IB27:_\ MO=S^\ESZ@GA?^ @4 ?/'@[X*^)_%!CN+J$Z3I[<^?=(0[#_9CZGZG ]Z^B/! MGPV\.^"(0=.M?-O2,/>SX:5O7!Z*/88]\UUU% !1110 4444 %%%% "$!E*L M 01@@]Z\A\=? ?2=>:6^\//'I5^V28=O^CR'Z#[GX<>U>OT4 ?#GB3PAKWA* M[^SZUITUL2<)(1NCD_W7'!_G6'7WQ>65KJ%J]K>VT-S;R##Q3('5A[@\5Y3X MF_9^\-:L7GT::;2+AN=B_O82?]TG(_ X'I0!\NT5Z3KWP-\:Z,6:WLXM3@'/ MF6N>*[S[-H MNG373 X=U&$C_P!YCP/Q-?07@7X"Z5HC17_B1X]4OEPPMP/]'C/N#R_XX'M7 MK=E8VFFVB6MC:PVUO&,)%"@15^@'%6* $551 JJ%51@ # I:** "BBB@ HH MHH R_$O_ "*NL?\ 7E-_Z :^%*^[?$$4DWAK58HD:21[.541!DL2AP .YKXR M_P"$$\8?]"IKG_@NF_\ B: .?KKOA=_R4_P[_P!?B_UJC_P@GC#_ *%37/\ MP73?_$UU'PX\'^)['XBZ%=7?AS5[>WBNU:26:QE1$'J25P!0!];T444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !7B_P 8OA(-=CF\1^'X -40;KFV M0?\ 'R!_$H_OC_Q[Z]?:** /@$@JQ5@01P0>U)7T;\9/A'_:*S^)_#MO_I@! M>\M(Q_KAWD0?WO4=^O7K\Y4 ?:/BW4O[(^%.I7H;:R:650^CLFU?U85\75]0 M?&_4_L7PAM+0-\U]+;PD>JJOF']4'YU\OT %%%% 'N'[-FF>;X@UK5"O%O:I M #[R-N_]I_K7T?7D'[.NF_9? =W?,N'O+UL'U1%"C]=U>OT %%%% !1110 4 M444 %%%% !1110 5\_?M&>%,-8>*K:/KBTN\#ZF-C_X\,_[M?0-9'B?0;?Q/ MX9U#1;G CNX2@8C.QNJM^# '\* /A>BK%]97&FZA4F"0?J<+_P "H ^B_@OX4_X1CP#;RSQ[ M;[4L74V1R%(^1?P7!QZL:]%I !@#@ 4M !1110 4444 %%%% !1110 44 M44 %?'OQFTW^S/BIK"A<1W#)<+[[T!;_ ,>W5]A5\W?M):;Y/B31M3"X%S:- M 3[QMG^4@H \1HHHH T-#U$Z1X@T[4E)S:74<_'^RP/]*^[E8,H92"I&01WK MX!K[<\ ZG_:_@#0;XMN>2RC#GU=1M;]0: /BN_\ ^0A<_P#75OYFJ]=/>^!O M%SWUPR^%M;*F5B"-/EP1G_=J#_A!/&'_ $*FN?\ @NF_^)H Y^BN@_X03QA_ MT*FN?^"Z;_XFC_A!/&'_ $*FN?\ @NF_^)H Y^BN@_X03QA_T*FN?^"Z;_XF MC_A!/&'_ $*FN?\ @NF_^)H Y^BN@_X03QA_T*FN?^"Z;_XFC_A!/&'_ $*F MN?\ @NF_^)H Y^BN@_X03QA_T*FN?^"Z;_XFC_A!/&'_ $*FN?\ @NF_^)H MY^BN@_X03QA_T*FN?^"Z;_XFC_A!/&'_ $*FN?\ @NF_^)H Y^OH7]F?_CS\ M2?\ 72W_ )25XU_P@GC#_H5-<_\ !=-_\37NO[/6AZOHMIKZZKI=]8&5X#&+ MJW>+?@/G&X#.,C\Z /:J^-/BU_R53Q!_U\#_ - 6OLNODWXG^$/$VH?$G7+J MR\.ZO ?&)Q_Q2NM_C82__$U-'\-_&LIPOA?51_O6S+_.@#EZ*[BW^#_C MZYQL\.3K_P!=)8X__0F%;=E^S]XWNB//33[,'KYUSG'_ 'P&H \LHKWW3/V: MG)#:MXC4#O':6^?_ !YC_P"RUWVB?!'P/HK+(^G/J,J_QWTGF#_O@84_B* / MEK0_#.M^);G[/HVF7-X^<$Q)\J_[S'A?Q(KVKP?^SMADNO%MZ".#]AM&Z^SR M?T7\Z]YMK6WLK=+>U@B@A086.) JK] .!4U %+2](T_1-/CL-+LX;2UC^[%$ MNT?4^I]SR:NT44 %%%% !1110 4444 %%%% &7XBT"Q\4:#>H?^!/_P!:C_AG_P # M_P#//4/_ )_^M7J5% 'EO\ PS_X'_YYZA_X$_\ UJ/^&?\ P/\ \\]0_P# MG_ZU>I44 >6_\,_^!_\ GGJ'_@3_ /6H_P"&?_ __//4/_ G_P"M7J5% 'EO M_#/_ ('_ .>>H?\ @3_]:C_AG_P/_P \]0_\"?\ ZU>I44 >6_\ #/\ X'_Y MYZA_X$__ %J/^&?_ /_ ,\]0_\ G_ZU>I44 >6_P##/_@?_GGJ'_@3_P#6 MH_X9_P# _P#SSU#_ ,"?_K5ZE10!Y;_PS_X'_P">>H?^!/\ ]:C_ (9_\#_\ M\]0_\"?_ *U>I44 >6_\,_\ @?\ YYZA_P"!/_UJ/^&?_ __ #SU#_P)_P#K M5ZE10!Y;_P ,_P#@?_GGJ'_@3_\ 6H_X9_\ _\ SSU#_P "?_K5ZE10!Y;_ M ,,_^!_^>>H?^!/_ -:C_AG_ ,#_ ///4/\ P)_^M7J5% 'EO_#/_@?_ )YZ MA_X$_P#UJ/\ AG_P/_SSU#_P)_\ K5ZE10!Y;_PS_P"!_P#GGJ'_ ($__6H_ MX9_\#_\ //4/_ G_ .M7J5% 'EO_ S_ .!_^>>H?^!/_P!:C_AG_P #_P#/ M/4/_ )_^M7J5% 'EO\ PS_X'_YYZA_X$_\ UJ/^&?\ P/\ \\]0_P# G_ZU M>I44 >6_\,_^!_\ GGJ'_@3_ /6H_P"&?_ __//4/_ G_P"M7J5% 'F=I\"/ M!=G>0744=_YD,BR)FYR,@Y';VKTRBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** #K7.ZKX#\*:V2VH>']/E<]9!"$<_\ EP?UKHJ* /+K_X M>![PDP17]CGM;W)('_?8:N?N?V:M)8G[+XAO8AV\V!9/Y%:]QHH ^?G_ &9G MR=GBQ3_O:?C_ -J4U/V9Y2?G\5H![6!/_M2OH.B@#PNV_9ITY3_I7B2ZE'_3 M*V6/^;-6_8?L^^";0@W']HWN.HFN-H/_ 'P%/ZUZK10!S6E?#WPAHA#6'AZP MC=>DCQ"1Q]&?)_6ND & , 4M% !1110 4444 %%%% !1110 4444 %%%% ! M1110 5%<6T%W"8;F&.:(]4D0,#^!J6B@#E;[X:>"M1):X\,Z<">IAB$1/_?& M*PI_@7X F/R:3-#_ -<[N7_V9C7H]% 'E_\ PH'P-NSY%]CT^U'_ JS!\"_ M $)^?2IIO^NEW+_[*PKT>B@#E+'X9^"=.(-OX9TXD=#-%YI'_?>:Z:WM;>SA M$-M!%!$.B1(%4?@*EHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O OC+\(M_VCQ3X ML3=QV\2M$OG21[25 ) M^1AGIWK&_P"%)?#S_H7O_)VX_P#CE>@ 8&!10!Y__P *2^'G_0O?^3MQ_P#' M*/\ A27P\_Z%[_R=N/\ XY7H%% &?HFAZ=X/%MJ:[9L#A9E&/_ !Y<'ZAJ[W]G_P *?V1X2EUVXCQ=:JV8\CE85)"_F MBJHP!^0H FHHHH **** "BBB@ HHHH **** "BBB@ K"\2^#M \80V\.O6 N MTMV+1#S7CVDC!Y1@>PK=HH \_P#^%)?#S_H7O_)VX_\ CE'_ I+X>?]"]_Y M.W'_ ,_\G;C_ ..5V&B:'IWAS2(=*TJW-O90;O+B M\QGV[F+'EB3U)/6M"B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ; **** "BBB@ HHHH **** "BBB@ HHHH __9 end EX-101.SCH 4 cnmd-20210728.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 cnmd-20210728_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 cnmd-20210728_pre.xml XBRL PRESENTATION FILE XML 7 form8k-26491_cnmd_htm.xml IDEA: XBRL DOCUMENT 0000816956 2021-07-28 2021-07-28 iso4217:USD shares iso4217:USD shares 0000816956 false 8-K 2021-07-28 CONMED CORPORATION DE 001-39218 16-0977505 11311 Concept Blvd Largo FL 33773 (727) 392-6464 false false false false Common Stock, $0.01 par value CNMD NYSE false XML 8 R1.htm IDEA: XBRL DOCUMENT v3.21.2
    Cover
    Jul. 28, 2021
    Cover [Abstract]  
    Document Type 8-K
    Amendment Flag false
    Document Period End Date Jul. 28, 2021
    Entity File Number 001-39218
    Entity Registrant Name CONMED CORPORATION
    Entity Central Index Key 0000816956
    Entity Tax Identification Number 16-0977505
    Entity Incorporation, State or Country Code DE
    Entity Address, Address Line One 11311 Concept Blvd
    Entity Address, City or Town Largo
    Entity Address, State or Province FL
    Entity Address, Postal Zip Code 33773
    City Area Code (727)
    Local Phone Number 392-6464
    Written Communications false
    Soliciting Material false
    Pre-commencement Tender Offer false
    Pre-commencement Issuer Tender Offer false
    Title of 12(b) Security Common Stock, $0.01 par value
    Trading Symbol CNMD
    Security Exchange Name NYSE
    Entity Emerging Growth Company false
    EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 1 96 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://conmed.com/role/Cover Cover Cover 1 false false All Reports Book All Reports form8k-26491_cnmd.htm cnmd-20210728.xsd cnmd-20210728_lab.xml cnmd-20210728_pre.xml ex99-1.htm http://xbrl.sec.gov/dei/2020-01-31 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form8k-26491_cnmd.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "definitionLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "form8k-26491_cnmd.htm" ] }, "labelLink": { "local": [ "cnmd-20210728_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "cnmd-20210728_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml" ] }, "schema": { "local": [ "cnmd-20210728.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2020-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "CNMD", "nsuri": "http://conmed.com/20210728", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "form8k-26491_cnmd.htm", "contextRef": "From2021-07-28to2021-07-28", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://conmed.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "form8k-26491_cnmd.htm", "contextRef": "From2021-07-28to2021-07-28", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://conmed.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://conmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://conmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://conmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://conmed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://conmed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://conmed.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://conmed.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r9", "r11", "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://conmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://conmed.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://conmed.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://conmed.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://conmed.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://conmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://conmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://conmed.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://conmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://conmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://conmed.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://conmed.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://conmed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://conmed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://conmed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://conmed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://conmed.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://conmed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://conmed.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://conmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://conmed.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://conmed.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://conmed.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://conmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://conmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://conmed.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://conmed.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://conmed.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://conmed.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://conmed.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://conmed.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://conmed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://conmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://conmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://conmed.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://conmed.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://conmed.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://conmed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://conmed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://conmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://conmed.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://conmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://conmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://conmed.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://conmed.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://conmed.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://conmed.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://conmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://conmed.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://conmed.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r10": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r11": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r12": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r13": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r14": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r15": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r16": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r17": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r18": { "Name": "Securities Act", "Number": "Section", "Publisher": "SEC", "Section": "12" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r9": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" } }, "version": "2.1" } ZIP 15 0001174947-21-000705-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001174947-21-000705-xbrl.zip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end